15/12/2006
London, UK – 15 December, 2006: ReGen Therapeutics Plc (the ‘Company’) announces that today it received notification from Mr Tigran Kalaydjian that he is beneficially interested in 21,000,000 ordinary shares of the Company representing 3.03% of the current issued share capital of the Company.
For further information, please contact:
Andrew Marshall
Tel. 020 7960 6007
Greycoat Communications